Stryker (NYSE: SYK) reported Q3 EPS of $2.12, $0.11 worse than the analyst estimate of $2.23. Revenue for the quarter came in at $4.5 billion versus the consensus estimate of $4.47 billion.

GUIDANCE:

Stryker sees FY2022 EPS of $9.15-$9.25, versus the consensus of $9.36.

• Considering our third quarter results, the strong order book for capital equipment and the sales momentum in our implant and capital businesses, we now expect full year 2022 organic net sales growth(2) to be in the range of 8.5% to 9.0%. If foreign currency exchange rates hold near current levels, we now expect net sales in the full year to be adversely impacted by approximately 4% and adjusted net earnings per diluted share(2) to be adversely impacted by approximately $0.35 to $0.40 in the full year. Based on our performance in the third quarter including consideration of continued inflationary pressures, together with our strong sales and additional cost reduction actions, and most significantly, the anticipated future impact of foreign currency, we now expect adjusted net earnings per diluted share(2) in the range of $9.15 to $9.25 per share.

For earnings history and earnings-related data on Stryker (SYK) click here.